Gilmore O'Neill - Mar 2, 2023 Form 4 Insider Report for Editas Medicine, Inc. (EDIT)

Role
CEO, Director
Signature
/s/ Damien Grierson, Attorney-in-Fact
Stock symbol
EDIT
Transactions as of
Mar 2, 2023
Transactions value $
$0
Form type
4
Date filed
3/6/2023, 03:30 PM
Previous filing
Jun 27, 2022
Next filing
Jun 7, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EDIT Common Stock Award $0 +50K +57.7% $0.00 137K Mar 2, 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EDIT Stock Option (right to buy) Award $0 +150K $0.00 150K Mar 2, 2023 Common Stock 150K $8.72 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The common stock received by the Reporting Person was in connection with the grant of a restricted stock unit award to the Reporting Person, for no consideration, and which is scheduled to vest over four years with 25% of the units vesting on March 2, 2024 and the remaining 75% of the units scheduled to vest in equal quarterly installments thereafter through March 2, 2027.
F2 This option was granted on March 2, 2023 and is scheduled to vest over four years in equal monthly installments beginning on April 2, 2023 through March 2, 2027.